Jan 12 (Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.


00


Reuters

Latest News

CNN: How to detox from a sodium habit you may not know you have

CTV News: Short stetch of Ste. Catherine St. to lose one lane of car traffic

CBC: Canada could start regulating barbecue brushes

BBC: Argentine anger over Heineken's 'Falklands' beer label

ABC: WATCH: Lyle Menendez describes prison reunion with brother

Daily Mail: Photographer shares portraits of mothers breastfeeding in public

Daily Mail: Love Island's Cara De La Hoyde and Nathan Massey play doting parents as they holiday with son

Daily Mail: England stars James Anderson and Stuart Broad set dates for County Championship comebacks

CNBC: Facebook runs ad campaign that sort of says sorry for data misuse scandal

CNBC: Southwest warns about drop in bookings after fatal engine failure

WashingtonPost: Fly Charts: Twitter’s Tepid Turnaround, Brokers Vs. Bots: Gadfly

CNN: 12 murders, 50 rapes: Suspect arrested after 40-year manhunt

BBC: Deutsche Bank plans 'significant' job cuts

Daily Mail: Video: Sharks are being treated to feeding frenzy near popular beaches

Daily Mail: Video: Father of Alfie Evans says son no longer needs intensive care

Jpost: 'Post' columnist Asa-El wins B'nai B'rith journalism award

FOX: Shooting at apartment complex in Illinois leaves 2 dead

NBC New York: Van Plunges Over NY Highway Barrier, Falls to Road Below

CNN: CNNMoney Before the Bell

ABC: 'Golden State Killer' victim's sister: 'I can finally breathe again'

Reuters: BRIEF-Milacron Holdings Posts Q1 GAAP Earnings Per Share $0.08

Reuters: UPDATE 1-Hershey's results beat on Amplify buy, demand in N. America

Reuters: BRIEF-International Paper Reports Q1 Earnings Per Share $1.74